GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fibrobiologics FBLG · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.96

-2.24%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Net income

−$18.6m

FY2021FY2026

Free cash flow

−$16.7m

FY2021FY2026

Shareholders' equity

$6.2m

FY2021FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Gross profit−$832,000−$573,000−$437,000−$94,000——
Research and development$7.4m$4.5m$2.4m$1.1m$521,000$669,000
Operating income−$16.6m−$13.7m−$8.9m−$4.5m−$1.6m−$1.2m
Net income−$18.6m−$11.2m−$16.5m−$5.1m−$1.6m−$1.2m
Diluted earnings per share-8.35-3.36-9.48-3.22-1.04-0.52

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Total assets$9.6m$16.4m$11.8m$4.8m$468,000—
Cash and short-term investments$4.9m$14.0m$9.2m$2.3m$407,000—
Total liabilities$3.5m$13.7m$10.6m$8.8m$1.8m—
Debt$2.4m$10.6m$1.7m$7.5m$1.3m—
Shareholders' equity$6.2m$2.7m$1.3m−$4.0m−$1.3m—
Shares outstanding2m3m2m2m2m2m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations−$16.4m−$11.9m−$6.4m−$4.1m−$1.4m−$1.2m
Capital spending−$262,000−$184,000−$495,000———
Free cash flow−$16.7m−$12.1m−$6.9m−$4.1m−$1.4m−$1.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$554,000—
Gross profit——−$234,000−$231,000−$206,000—$277,000—
Operating income−$4.0m−$5.1m−$3.1m−$5.0m−$4.5m−$4.5m−$3.7m−$3.4m
Net income−$4.1m−$5.0m−$3.2m−$5.8m−$4.7m−$5.0m−$3.1m−$500,000
Diluted earnings per share-1.84-2.24-0.98-1.74-1.40-1.49-1.78-0.29
Cash from operations−$3.0m−$4.0m−$3.0m−$3.0m−$3.0m−$5.0m−$3.0m−$2.0m
Total assets$7.9m$5.9m$9.6m$8.7m$13.9m$11.4m$16.4m$10.5m
Cash and short-term investments$3.5m$1.5m$4.9m$4.9m$8.8m$8.7m$14.0m$7.8m
Debt$382,000$969,000$706,000$5.2m$8.7m$6.3m$9.6m$507,000
Shareholders' equity$4.6m$2.6m$6.2m$125,000$860,000$2.4m$2.7m$2.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income55.0%70.1%—
Net income53.8%74.0%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024
Price to earnings-0.1-0.8-2.4

Share price return

Finished calendar years

20252024
Return-87%-81%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 30 Mar 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.